Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 5 patents
10 readers on Mendeley
  • Article usage
  • Citations to this article (115)

Advertisement

Free access | 10.1172/JCI108753

Radioimmunoassay of Human Apolipoprotein CII: A STUDY IN NORMAL AND HYPERTRIGLYCERIDEMIC SUBJECTS

M. L. Kashyap, L. S. Srivastava, C. Y. Chen, G. Perisutti, M. Campbell, R. F. Lutmer, and C. J. Glueck

Lipid Research Clinic, Cincinnati, Ohio 45267

The Radioimmunoassay Laboratory of the Division of Metabolism, and General Clinical Research Center, Cincinnati, Ohio 45267

Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, Ohio 45267

Find articles by Kashyap, M. in: PubMed | Google Scholar

Lipid Research Clinic, Cincinnati, Ohio 45267

The Radioimmunoassay Laboratory of the Division of Metabolism, and General Clinical Research Center, Cincinnati, Ohio 45267

Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, Ohio 45267

Find articles by Srivastava, L. in: PubMed | Google Scholar

Lipid Research Clinic, Cincinnati, Ohio 45267

The Radioimmunoassay Laboratory of the Division of Metabolism, and General Clinical Research Center, Cincinnati, Ohio 45267

Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, Ohio 45267

Find articles by Chen, C. in: PubMed | Google Scholar

Lipid Research Clinic, Cincinnati, Ohio 45267

The Radioimmunoassay Laboratory of the Division of Metabolism, and General Clinical Research Center, Cincinnati, Ohio 45267

Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, Ohio 45267

Find articles by Perisutti, G. in: PubMed | Google Scholar

Lipid Research Clinic, Cincinnati, Ohio 45267

The Radioimmunoassay Laboratory of the Division of Metabolism, and General Clinical Research Center, Cincinnati, Ohio 45267

Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, Ohio 45267

Find articles by Campbell, M. in: PubMed | Google Scholar

Lipid Research Clinic, Cincinnati, Ohio 45267

The Radioimmunoassay Laboratory of the Division of Metabolism, and General Clinical Research Center, Cincinnati, Ohio 45267

Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, Ohio 45267

Find articles by Lutmer, R. in: PubMed | Google Scholar

Lipid Research Clinic, Cincinnati, Ohio 45267

The Radioimmunoassay Laboratory of the Division of Metabolism, and General Clinical Research Center, Cincinnati, Ohio 45267

Department of Medicine, University of Cincinnati, College of Medicine, Cincinnati, Ohio 45267

Find articles by Glueck, C. in: PubMed | Google Scholar

Published July 1, 1977 - More info

Published in Volume 60, Issue 1 on July 1, 1977
J Clin Invest. 1977;60(1):171–180. https://doi.org/10.1172/JCI108753.
© 1977 The American Society for Clinical Investigation
Published July 1, 1977 - Version history
View PDF
Abstract

A specific, precise, and sensitive double-antibody radioimmunoassay for the measurement of human apolipoprotein CII (apoCII) was developed. ApoCII was labeled with 125I (chloramine-T) and monospecific antibody was raised in rabbits. No appreciable cross-reactivity with apolipoproteins CI, CIII, AI, AII, low density lipoproteins, and lipoprotein-free plasma was observed. Lipoproteins containing apoCII displaced the standard curve in parallel. ApoCII measurement was not affected by pretreatment of plasma with tetramethylurea, ethanol-diethyl ether, or heating.

Mean (±SE) plasma-immunoreactive apoCII in 47 normotriglyceridemic subjects was 51.8±3.2 μg/ml, generally comparable with previous estimates of its concentration by other methods. ApoCII levels in 9 subjects with type IIB lipoprotein pattern, 14 with the type IV lipoprotein pattern, and 5 with type V lipoprotein pattern were respectively, 89.9±4.6, 85.4±6.9, 132.8±21.0 μg/ml, all higher than normals (P < 0.001). Plasma apoCII and triglyceride concentrations correlated in normo- and hypertriglyceridemics (r = 0.36 and 0.58, P < 0.05). Plasma triglycerides correlated inversely with the fraction of total apoCII in very low density lipoprotein (VLDL)-free plasma (r = −0.75, P < 0.01). There was no correlation between plasma apoCII and high density lipoprotein cholesterol.

In normotriglyceridemics, VLDL apoCII levels correlated with in vitro lipoprotein lipase (LPL) activator activities (r = 0.89, P < 0.01). In hypertriglyceridemic subjects the mean concentrations of apoCII per milligrams VLDL protein, LPL activator activity per milligrams VLDL protein, and LPL activator activity per micrograms VLDL apoCII were all lower than in normotriglyceridemics, P < 0.05.

As plasma triglycerides and apoCII increase, apoCII is redistributed from high density lipoprotein to VLDL. However, the amount of apoCII per milligram VLDL protein and its LPL activator potency per milligram VLDL protein are reduced. These factors may contribute to impaired VLDL catabolism.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 171
page 171
icon of scanned page 172
page 172
icon of scanned page 173
page 173
icon of scanned page 174
page 174
icon of scanned page 175
page 175
icon of scanned page 176
page 176
icon of scanned page 177
page 177
icon of scanned page 178
page 178
icon of scanned page 179
page 179
icon of scanned page 180
page 180
Version history
  • Version 1 (July 1, 1977): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (115)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 5 patents
10 readers on Mendeley
See more details